Clinical Trial Update: Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes [Phase 2]

View source ↗

Summary

Phase 2 trial results for inhaled CVT 301 in Parkinson's disease patients evaluated for treating OFF episodes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• CVT-301 (levodopa inhalation powder)

Snippet

Sponsor: Acorda Therapeutics | Conditions: Idiopathic Parkinson's Disease | Phase 2 | Status: COMPLETED